Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for HALO

Stock NameHalozyme Therapeutics Inc
TickerHALO(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS40637H1095
LEI529900242I3SV9AGM753

Show aggregate HALO holdings

News associated with HALO

Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of “Hold” from Analysts
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been assigned a consensus rating of “Hold” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and four have issued a buy recommendation on the […] - 2025-08-26 02:16:51
Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High Following Analyst Upgrade
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday after Morgan Stanley raised their price target on the stock from $75.00 to $80.00. Morgan Stanley currently has an overweight rating on the stock. Halozyme Therapeutics traded as high as $70.70 and last traded at […] - 2025-08-20 02:34:49
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Lessened by Vanguard Group Inc.
Vanguard Group Inc. trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 3.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,831,503 shares of the biopharmaceutical company’s stock after selling 450,211 shares during […] - 2025-08-13 05:43:01
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,748,851 shares of the biopharmaceutical company’s stock after selling 34,326 shares during […] - 2025-08-12 05:24:49
Halozyme Therapeutics (NASDAQ:HALO) Upgraded to “Overweight” at Morgan Stanley
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report released on Wednesday, Marketbeat Ratings reports. The brokerage currently has a $75.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $62.00. Morgan Stanley’s […] - 2025-08-08 02:40:46
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Boosted by LPL Financial LLC
LPL Financial LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 17.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 242,432 shares of the biopharmaceutical company’s stock after acquiring an additional 35,429 shares during the period. LPL Financial LLC’s holdings in […] - 2025-08-07 04:46:47
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.70 Consensus Price Target from Analysts
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. […] - 2025-08-04 02:59:02
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by IFP Advisors Inc
IFP Advisors Inc increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2,374.1% during the first quarter, HoldingsChannel.com reports. The fund owned 2,103 shares of the biopharmaceutical company’s stock after buying an additional 2,018 shares during the period. IFP Advisors Inc’s holdings in Halozyme Therapeutics were worth $134,000 as of its most […] - 2025-07-29 04:32:50
Envestnet Asset Management Inc. Acquires 1,161 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Envestnet Asset Management Inc. raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 0.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 303,774 shares of the biopharmaceutical company’s stock after acquiring an additional 1,161 shares during […] - 2025-07-17 04:50:57
Teacher Retirement System of Texas Sells 3,278 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Teacher Retirement System of Texas trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 8.7% in the first quarter, Holdings Channel reports. The institutional investor owned 34,238 shares of the biopharmaceutical company’s stock after selling 3,278 shares during the quarter. Teacher Retirement System of Texas’ holdings in Halozyme Therapeutics were worth $2,185,000 […] - 2025-07-10 05:14:10
Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.90
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has received a consensus rating of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating on the company. The average […] - 2025-07-10 03:07:07
Principal Financial Group Inc. Has $24.25 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Principal Financial Group Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 380,021 shares of the biopharmaceutical company’s stock after buying an additional 3,826 shares during the quarter. Principal Financial Group […] - 2025-07-09 05:51:39
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 39.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,742 shares of the biopharmaceutical company’s stock after selling 3,153 shares during the quarter. Vontobel Holding Ltd.’s holdings in Halozyme […] - 2025-07-09 05:00:49
Envestnet Portfolio Solutions Inc. Has $721,000 Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Envestnet Portfolio Solutions Inc. lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.2% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,292 shares of the biopharmaceutical company’s stock after selling 6,143 shares during the period. Envestnet Portfolio Solutions Inc.’s […] - 2025-06-26 04:38:48
Janney Montgomery Scott LLC Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Janney Montgomery Scott LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,123 shares of the biopharmaceutical company’s stock after purchasing an additional 6,392 shares during […] - 2025-06-19 05:50:56
SeaCrest Wealth Management LLC Invests $213,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
SeaCrest Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,333 shares of the biopharmaceutical company’s stock, valued at approximately $213,000. Several other institutional […] - 2025-06-09 05:54:51
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Wellington Management Group LLP
Wellington Management Group LLP lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 12.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 57,370 shares of the biopharmaceutical company’s stock after selling 7,787 shares during the quarter. Wellington Management Group LLP’s holdings in Halozyme Therapeutics were worth $2,743,000 at the […] - 2025-06-06 05:34:51
Tidal Investments LLC Has $381,000 Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Tidal Investments LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 61.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,978 shares of the biopharmaceutical company’s stock after selling 12,598 shares during the period. Tidal Investments LLC’s holdings […] - 2025-05-30 05:47:04
Friday's ETF with Unusual Volume: GFLW
The VictoryShares Free Cash Flow Growth ETF is seeing unusually high volume in afternoon trading Friday, with over 2.9 million shares traded versus three month average volume of about 196,000. Shares of GFLW were up about 0.7% on the day. Components of that ETF with the highes - 2025-05-16 16:18:34
Baird Financial Group Inc. Buys 221 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Baird Financial Group Inc. raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,119 shares of the biopharmaceutical company’s stock after acquiring an additional 221 shares during the period. […] - 2025-05-16 05:31:14
Halozyme Therapeutics Reaches Analyst Target Price
In recent trading, shares of Halozyme Therapeutics Inc (Symbol: HALO) have crossed above the average analyst 12-month target price of $68.12, changing hands for $70.14/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra - 2025-05-08 09:19:58
Hsbc Holdings PLC Acquires 3,289 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 52.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,615 shares of the biopharmaceutical company’s stock after purchasing an additional 3,289 shares during the quarter. Hsbc […] - 2025-05-08 05:10:47
Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High After Strong Earnings
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $69.07 and last traded at $68.06, with a volume of 1856311 shares trading hands. The stock had previously closed at $59.38. The […] - 2025-05-08 03:08:54
4,426 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Marshall Wace LLP
Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund bought 4,426 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. Other institutional investors and hedge funds have also made changes to their positions in the company. Heck […] - 2025-05-06 04:30:49
Halozyme Files Patent Infringement Lawsuit Against Merck
(RTTNews) - Halozyme Therapeutics (HALO) filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of Merck's cancer medicine, Keytruda, infringes multiple patents that Halozyme filed - 2025-04-24 10:08:04
Legal & General Group Plc Decreases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Legal & General Group Plc lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 225,427 shares of the biopharmaceutical company’s stock after selling 3,197 shares during the quarter. Legal & General Group Plc’s holdings in Halozyme Therapeutics were worth $10,778,000 […] - 2025-04-17 06:08:53
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC
CIBC Private Wealth Group LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,053 shares of the biopharmaceutical company’s stock after selling 963,451 shares during […] - 2025-04-08 05:22:55
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement System
California Public Employees Retirement System cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 213,687 shares of the biopharmaceutical company’s stock after selling 15,172 shares during the quarter. […] - 2025-04-07 05:56:55
Schroder Investment Management Group Sells 9,933,836 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Schroder Investment Management Group cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,503 shares of the biopharmaceutical company’s stock after selling 9,933,836 shares during the quarter. Schroder Investment Management […] - 2025-04-06 05:30:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc HALO holdings

DateNumber of HALO Shares HeldBase Market Value of HALO SharesLocal Market Value of HALO SharesChange in HALO Shares HeldChange in HALO Base ValueCurrent Price per HALO Share HeldPrevious Price per HALO Share Held
2025-10-16 (Thursday)49,721USD 3,325,340USD 3,325,340
2025-10-15 (Wednesday)49,721USD 3,299,486USD 3,299,486
2025-10-13 (Monday)48,785USD 3,187,124USD 3,187,124
2025-10-09 (Thursday)48,785USD 3,176,391USD 3,176,391
2025-10-07 (Tuesday)48,785USD 3,220,786USD 3,220,786
2025-10-06 (Monday)48,629USD 3,256,684USD 3,256,684
2025-10-03 (Friday)48,629USD 3,354,428HALO holding decreased by -131785USD 3,354,4280USD -131,785 USD 68.98 USD 71.69
2025-10-02 (Thursday)48,629HALO holding increased by 156USD 3,486,213HALO holding decreased by -146354USD 3,486,213156USD -146,354 USD 71.69 USD 74.94
2025-10-01 (Wednesday)48,473USD 3,632,567HALO holding increased by 77557USD 3,632,5670USD 77,557 USD 74.94 USD 73.34
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of HALO by Blackrock for IE00B3VWM098

Show aggregate share trades of HALO

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-02BUY156 71.690* 57.18
2025-09-30BUY312 73.340* 56.98
2025-09-11BUY624 77.530* 56.45
2025-08-21SELL-122 71.610* 56.36 Profit of 6,876 on sale
2025-07-31BUY366 59.970* 56.25
2025-07-17BUY1,609 57.805* 56.16
2025-06-30SELL-232 52.020* 56.24 Profit of 13,048 on sale
2025-06-25SELL-116 52.320* 56.32 Profit of 6,534 on sale
2025-06-20SELL-232 52.810* 56.39 Profit of 13,083 on sale
2025-05-23BUY116 54.540* 56.76
2025-05-19SELL-116 53.295* 56.87 Profit of 6,597 on sale
2025-05-15SELL-348 48.950* 56.98 Profit of 19,831 on sale
2025-05-12SELL-116 66.580* 57.04 Profit of 6,617 on sale
2025-05-09SELL-117 65.870* 56.96 Profit of 6,664 on sale
2025-04-30SELL-117 61.420* 56.55 Profit of 6,617 on sale
2025-04-24SELL-234 59.250* 56.40 Profit of 13,198 on sale
2025-04-17SELL-117 58.790* 56.30 Profit of 6,587 on sale
2025-04-15SELL-351 61.280* 56.22 Profit of 19,734 on sale
2025-04-14SELL-351 61.390* 56.16 Profit of 19,714 on sale
2025-04-09SELL-468 60.650* 56.05 Profit of 26,232 on sale
2025-04-07SELL-819 59.350* 55.99 Profit of 45,860 on sale
2025-04-04BUY409 59.770* 55.95
2025-03-31BUY112 63.810* 55.70
2025-03-19SELL-224 64.300* 54.76 Profit of 12,266 on sale
2025-03-14SELL-672 62.270* 54.43 Profit of 36,577 on sale
2025-03-13SELL-224 61.060* 54.34 Profit of 12,171 on sale
2025-03-12SELL-3,808 60.890* 54.24 Profit of 206,546 on sale
2025-03-07SELL-224 60.980* 53.92 Profit of 12,078 on sale
2025-03-06SELL-336 60.150* 53.82 Profit of 18,085 on sale
2025-03-03SELL-112 57.960* 53.60 Profit of 6,003 on sale
2025-02-28BUY6,605 59.150* 53.50
2025-02-26SELL-93 57.920* 53.36 Profit of 4,962 on sale
2025-02-25SELL-279 57.990* 53.28 Profit of 14,865 on sale
2025-02-18BUY465 57.900* 52.85
2025-02-13BUY93 58.610* 52.51
2025-02-12BUY93 58.110* 52.40
2025-02-11BUY279 57.330* 52.30
2025-02-06BUY837 57.940* 51.95
2025-01-27BUY93 55.860* 50.98
2024-12-30BUY465 47.990* 50.88
2024-12-06BUY372 48.400* 51.08
2024-12-05BUY93 48.060* 51.19
2024-12-04BUY465 48.610* 51.28
2024-11-29BUY465 48.200* 51.62
2024-11-27BUY368 48.470* 51.89
2024-11-26BUY92 47.790* 52.08
2024-11-21BUY460 45.700* 52.80
2024-11-20BUY276 45.760* 53.20
2024-11-18BUY1,104 42.570* 54.38
2024-11-12BUY736 59.610* 54.04
2024-11-08BUY460 60.980* 53.54
2024-11-07BUY1,380 59.650* 53.07
2024-11-06BUY184 60.630* 52.44
2024-10-31BUY92 50.570* 50.54
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of HALO

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19371,468246613,71260.5%
2025-09-18369,20950726,19450.8%
2025-09-17256,6119,792553,70146.3%
2025-09-16228,40390394,05258.0%
2025-09-15227,697268471,46148.3%
2025-09-12221,090110427,51051.7%
2025-09-11514,0761,959993,63351.7%
2025-09-10166,289386439,00237.9%
2025-09-09273,054401595,14645.9%
2025-09-08673,4827,545952,32470.7%
2025-09-05290,02413,523686,83942.2%
2025-09-04407,7375,358712,76957.2%
2025-09-03550,40413,7061,063,45351.8%
2025-09-02616,27811,835991,44262.2%
2025-08-29269,93076,054395,06868.3%
2025-08-28433,7604,556628,92169.0%
2025-08-271,260,6114,5391,702,44974.0%
2025-08-26588,7022,967980,20060.1%
2025-08-25371,5652,132648,27057.3%
2025-08-22876,545177,5071,274,83468.8%
2025-08-21443,68860,024724,49661.2%
2025-08-20591,075169,034869,55068.0%
2025-08-19935,00612,4211,715,49554.5%
2025-08-18449,8017,338718,19462.6%
2025-08-15329,4697,019525,00662.8%
2025-08-14516,84366,827759,57868.0%
2025-08-13389,9275,826908,60642.9%
2025-08-12781,37413,6031,175,10266.5%
2025-08-11586,47259,410817,35871.8%
2025-08-08285,72819,152668,99942.7%
2025-08-07408,49314863,23347.3%
2025-08-061,204,1564,8502,539,38747.4%
2025-08-05583,0452901,069,04354.5%
2025-08-04177,608200363,85148.8%
2025-08-01207,308307616,18733.6%
2025-07-31622,1231471,098,49656.6%
2025-07-30274,3231,375540,02850.8%
2025-07-29318,0793,010584,12254.5%
2025-07-28194,988129416,26346.8%
2025-07-25115,0240312,07436.9%
2025-07-24144,85426,732266,45354.4%
2025-07-23154,87130,676443,14434.9%
2025-07-22203,2470381,32153.3%
2025-07-21144,9641,656318,07245.6%
2025-07-18136,0301,809379,30135.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.